Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofiâs Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Companyâs products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSNY
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSanofi SA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 01, 2002
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1994
āļāļĩāļāļĩāđāļMr. Paul Hudson, Ph.D.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ84587
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒDepository Receipt
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 01
āļāļĩāđāļāļĒāļđāđ46 Avenue de la Grande Armee
āđāļĄāļ·āļāļPARIS
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻFrance
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ75017
āđāļāļĢāļĻāļąāļāļāđ33153774000
āđāļ§āđāļāđāļāļāđhttps://www.sanofi.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSNY
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 01, 2002
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1994
Ms. Barbara Lavernos
Director
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
Dr. Antoine Yver, M.D.
Independent Director
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Ms. Clotilde Delbos
Independent Director
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Ms. Barbara Lavernos
Director
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
Dr. Antoine Yver, M.D.
Independent Director
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
VanEck Pharmaceutical ETF
Putnam Focused Large Cap Value ETF
Invesco International Dividend Achievers ETF
Pacer Global Cash Cows Dividend ETF
Altrius Global Dividend ETF
Invesco Nasdaq Biotechnology ETF
ProShares Ultra Nasdaq Biotechnology
T Rowe Price Equity Income ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
VanEck Pharmaceutical ETF
āļŠāļąāļāļŠāđāļ§āļ4.48%
Simplify Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ3.84%
Putnam Focused Large Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ2.55%
Brandes US Value ETF
āļŠāļąāļāļŠāđāļ§āļ2.08%
Invesco International Dividend Achievers ETF
āļŠāļąāļāļŠāđāļ§āļ2.05%
Pacer Global Cash Cows Dividend ETF
āļŠāļąāļāļŠāđāļ§āļ1.93%
Altrius Global Dividend ETF
āļŠāļąāļāļŠāđāļ§āļ1.8%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ1.59%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ1.55%
T Rowe Price Equity Income ETF
āļŠāļąāļāļŠāđāļ§āļ1.19%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
23.51B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020